ClinicalTrials.gg
CompletedNCT00402103Updated Mar 10, 2011Results posted

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

A Phase 3 interventional study of Aliskiren and Amlodipine in Hypertension, sponsored by Novartis. Completed at 8 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-10.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
556
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 89 studies testing aliskiren in Hypertension — none open to participants now, none under way, none of them phase 3. aliskiren · Hypertension.

Enrollment
29th of 89
556 · median 253
Started
2006
with 10 others
Phase 3
38 of 89
none open now
Registered
31st of 89
by date
Lead sponsor
52 of 89
Novartis

Among the 89 studies testing aliskiren in Hypertension, this one is the 29th largest by enrollment, is one of 11 that started in 2006, is one of 38 in phase 3, and was the 31st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 89 studies testing aliskiren in Hypertension is open now. The open studies under Hypertension, anywhere →

About aliskiren

aliskiren: first FDA approval 2007 (TEKTURNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 89 studies testing aliskiren in Hypertension as a file.
02

Study summary

To assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg / amlodipine 10 mg in patients with essential hypertension (Mean Sitting Diastolic Blood Pressure [msDBP] ≥ 90 mmHg and \< 110 mmHg).

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension, aliskiren, amlodipine, HCTZ, blood pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients 18 years of age or older
  • Male or female patients are eligible
  • For newly diagnosed/untreated patients with essential hypertension defined as msDBP ≥ 90 and \< 110 mmHg at Visit 1 and Visit 4
  • For previously treated patients with essential hypertension defined as msDBP ≥ 90 and \< 110 mmHg after 2 to 4 weeks of washout (Visit 4)

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension
  • History or evidence of a secondary form of hypertension
  • History of Hypertensive encephalopathy or cerebrovascular accident.

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
556 participants (actual)

Study arms

  • Experimental
    Aliskiren/Amlodipine

    Drug: Aliskiren · Drug: Amlodipine

  • Experimental
    Aliskiren/Amlodipine/HCTZ

    Drug: Aliskiren · Drug: Amlodipine · Drug: Hydrochlorothiazide

Interventions

  • All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration

  • All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration

  • Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.

06

What researchers measure

Primary outcomes

  1. Overall Percentage of Patients With Adverse Events

    Time frame: 52 weeks

Secondary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (msDBP)From Baseline to the Indicated Time Points

    Time frame: Baseline, Week 2, Week 4, Week 6, Week 10, Week 14, Week 28, Week 41 and Week 54

  2. Percentage of Patients Achieving a Blood Pressure Control Target of <140/90 mmHg

    Time frame: Baseline, Week 2, Week 10, Week 28 and Week 54

  3. Percentage of Patients Achieving a Response in Mean Sitting Diastolic Blood Pressure (msDBP)

    Time frame: Baseline, Week 2, Week 10, Week 28 and Week 54

07

Results

Posted Jan 11, 2011

Participant flow

Participant flow — Overall Study
MilestoneAliskiren/AmlodipineAliskiren/Amlodipine/HCTZ
Started47086
Completed37973
Not completed9113
Withdrew: Adverse event607
Withdrew: Unsatisfactory therapeutic effect12
Withdrew: Condition no longer requires study drug20
Withdrew: Protocol deviation80
Withdrew: Patient withdrew consent121
Withdrew: Lost to follow-up63
Withdrew: Administrative problems20

Outcome measures

PrimaryOverall Percentage of Patients With Adverse Events
Time frame:
52 weeks
Reported as:
Number · Percentage of Participants
Overall Percentage of Patients With Adverse Events
Percentage of ParticipantsAliskiren 150mg/ Amlodipine 5mg AloneAliskiren 300mg/ Amlodipine 10mg AloneAliskiren 300mg/ Amlodipine 10mg/ HCTZ
Overall Percentage of Patients With Adverse Events23.671.257.0
SecondaryChange in Mean Sitting Diastolic Blood Pressure (msDBP)From Baseline to the Indicated Time Points
Time frame:
Baseline, Week 2, Week 4, Week 6, Week 10, Week 14, Week 28, Week 41 and Week 54
Reported as:
Mean · mm Hg
Change in Mean Sitting Diastolic Blood Pressure (msDBP)From Baseline to the Indicated Time Points
mm HgAliskiren/AmlodipineAliskiren/Amlodipine/HCTZ
Week 2 (Visit 5)-8.7 ± 6.94-5.9 ± 6.05
Week 4 (Visit 6)-14.0 ± 6.88-11.9 ± 5.58
Week 6 (Visit 7)-15.7 ± 6.96-11.5 ± 7.36
Week 10 (Visit 8)-16.3 ± 6.69-9.3 ± 7.22
Week 14 (Visit 9)-17.1 ± 6.84-13.1 ± 7.64
Week 28 (Visit 10)-16.7 ± 7.15-14.7 ± 8.22
Week 41 (Visit 11)-17.0 ± 7.26-15.4 ± 6.86
Week 54 (Visit 12)-16.3 ± 7.13-15.3 ± 6.55
Week 54 (Visit 12) (LOCF)-15.7 ± 7.61-14.2 ± 7.90
SecondaryPercentage of Patients Achieving a Blood Pressure Control Target of <140/90 mmHg
Time frame:
Baseline, Week 2, Week 10, Week 28 and Week 54
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving a Blood Pressure Control Target of <140/90 mmHg
Percentage of patientsAliskiren/AmlodipineAliskiren/Amlodipine/HCTZ
Week 2 (Visit 5)35.3 ± 88.08.1
Week 10 (Visit 8)88.016.3
Week 28 (Visit 10)88.256.8
Week 54 (Visit 12)82.062.2
Week 54 (Visit 12) (LOCF)77.358.1
SecondaryPercentage of Patients Achieving a Response in Mean Sitting Diastolic Blood Pressure (msDBP)
Time frame:
Baseline, Week 2, Week 10, Week 28 and Week 54
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving a Response in Mean Sitting Diastolic Blood Pressure (msDBP)
Percentage of patientsAliskiren/AmlodipineAliskiren/Amlodipine/HCTZ
Week 2 (Visit 5)61.238.4
Week 10 (Visit 8)96.861.6
Week 28 (Visit 10)95.985.2
Week 54 (Visit 12)93.289.2
Week 54 (Visit 12) (LOCF)90.684.9

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aliskiren 150mg/ Amlodipine 5mg Alone—0/556 (0%)14/556 (2.5%)
Aliskiren 300mg/ Amlodipine 10mg Alone—13/546 (2.4%)138/546 (25.3%)
Aliskiren 300mg/ Amlodipine 10mg/ HCTZ—2/86 (2.3%)21/86 (24.4%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventAliskiren 150mg/ Amlodipine 5mg AloneAliskiren 300mg/ Amlodipine 10mg AloneAliskiren 300mg/ Amlodipine 10mg/ HCTZ
GangreneInfections and infestations0/5560/5461/86
HypotensionVascular disorders0/5560/5461/86
Atrial fibrillationCardiac disorders0/5561/5460/86
DiarrhoeaGastrointestinal disorders0/5561/5460/86
Intestinal ischaemiaGastrointestinal disorders0/5561/5460/86
AmoebiasisInfections and infestations0/5561/5460/86
GastroenteritisInfections and infestations0/5561/5460/86
Post procedural infectionInfections and infestations0/5561/5460/86
Respiratory tract infectionInfections and infestations0/5561/5460/86
Acetabulum fractureInjury, poisoning and procedural complications0/5561/5460/86
Most frequent other events
Most frequent other events
EventAliskiren 150mg/ Amlodipine 5mg AloneAliskiren 300mg/ Amlodipine 10mg AloneAliskiren 300mg/ Amlodipine 10mg/ HCTZ
Oedema peripheralGeneral disorders8/556108/54612/86
Upper respiratory tract infectionInfections and infestations5/55632/5465/86
Muscle spasmsMusculoskeletal and connective tissue disorders1/5565/5465/86

Baseline characteristics

Age Continuous
Age Continuous(years)Aliskiren/AmlodipineAliskiren/Amlodipine/HCTZTotal
Mean54.2 ± 11.6655.7 ± 11.3354.4 ± 11.61
Sex: Female, Male
Sex: Female, Male(Participants)Aliskiren/AmlodipineAliskiren/Amlodipine/HCTZTotal
Female19630226
Male27456330
08

Study locations

8 sites
  • Investigative Site
    Santa Fe, New Mexico, United States
  • Investigator Site
    Investigative Site, Belgium
  • Investigative Center
    Investigative Center, Denmark
  • Investigative Site
    Investigative Site, Finland
  • Investigative Center
    Investigative Center, Germany
  • Investigative Site
    Investigative Site, Iceland
  • Investigative Site
    Investigative Site, India
  • Investigative Site
    Investigative Site, Switzerland
09

References and documents

Publications

  • Littlejohn TW 3rd, Trenkwalder P, Hollanders G, Zhao Y, Liao W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin. 2009 Apr;25(4):951-9. doi: 10.1185/03007990902785845. PubMed 19257800 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2006
First posted
Nov 22, 2006
Start
Nov 2006
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Jan 11, 2011
Last update
Mar 10, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00402103
Lead sponsor
Novartis
First posted
Nov 22, 2006
Start date
Nov 2006
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jan 11, 2011
Last update
Mar 10, 2011

Study contacts

Novartis Pharmaceuticals
study chair · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aliskiren · Amlodipine

Start the discussion